Anteris Technologies Global Corp. (ASX:AVR)
7.15
-0.30 (-4.03%)
Jun 13, 2025, 4:10 PM AEST
ASX:AVR Revenue
Anteris Technologies Global had revenue of $556.00K USD in the quarter ending March 31, 2025, with 2.14% growth. This brings the company's revenue in the last twelve months to $2.49M, down -8.85% year-over-year. In the year 2024, Anteris Technologies Global had annual revenue of $2.70M, down -1.17%.
Revenue (ttm)
$2.49M
Revenue Growth
-8.85%
P/S Ratio
67.21
Revenue / Employee
$18.33K
Employees
136
Market Cap
268.66M AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
Dec 31, 2020 | 5.46M | -6.54M | -54.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Telix Pharmaceuticals | 783.21M |
Ramsay Health Care | 17.12B |
Ansell | 3.00B |
Mesoblast | 9.16M |
Anteris Technologies Global News
- 2 months ago - Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewsWire
- 2 months ago - Anteris Reports One-Year Patient Outcomes for DurAVR® THV - GlobeNewsWire
- 3 months ago - Anteris Technologies Global Corp. reports FY results - Seeking Alpha
- 3 months ago - Anteris Reports 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast - Benzinga
- 5 months ago - Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst - Benzinga
- 6 months ago - Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering - Business Wire
- 6 months ago - U.S. IPO Weekly Recap: ServiceTitan Shines In 3 IPO Week - Seeking Alpha